Stadtlanders Pharmacy

CDC HIV/STD/TB Prevention News Update

Thursday, February 17, 2000
The CDC National Center for HIV, STD, and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases, and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Peer-Review Headlines

General Meadia


Peer-Review Headlines

Effect of Breastfeeding on Infant and Child Mortality Due to Infectious Diseases in Less Developed Countries: A Pooled Analysis

"Effect of Breastfeeding on Infant and Child Mortality Due to Infectious Diseases in Less Developed Countries: A Pooled Analysis" Lancet (02/05/00) Vol. 355, No. 9202, P. 451
An analysis of several studies from six different countries included information on the deaths of 1,223 children under age two. The studies included babies that were breastfed into their second year. By studying the extent that breastfeeding can protect infants against child mortality, researchers found ways to shape policies regarding HIV-positive mothers breastfeeding their children. The six studies used show that acute respiratory infections and diarrhea were the chief causes of death from infectious diseases in three of the studies. In the African subjects, almost all the children were breastfed, while the greatest protection provided by breastfeeding was seen in Pakistan. Overall, protection provided by breastmilk decreased with age during infancy, and is a consideration for new policies. The question of replacing breastmilk of HIV-positive mothers must also be weighed against the cost and availability of milk substitutes. The authors, from the World Health Organization Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality, note "there is a wide agreement that the final decision on whether or not to breastfeed if a woman is HIV-positive should reside with the mother and the family."

Caesarean Section and Antiretroviral Treatment

Lancet (02/05/00) Vol. 355, No. 9202, P. 496; Ricci, E.; Parazzini, F.; Pardi, G.
In a letter to the editor, Italian researchers report the completion of a study on caesarean section versus vaginal delivery in relation to the risk of passing HIV to a child. The final results, which follow the March 1999 publication in The Lancet of the European Mode of Delivery Collaboration Trial, include the infection status of another 15 children and indicate that only one infant, who was delivered vaginally, was infected with HIV-1. Of 414 women taking part, 10.6 percent gave birth to HIV-infected babies during vaginal delivery, and 1.7 percent during caesarean section. All mothers received zidovudine during pregnancy, and the researchers note that the overall complication rate was low.


General Media

Cheaper AIDS Drugs Sought

Washington Times (02/17/00) P. A15; Kurlantzick, Joshua
A United Nations trade conference in Bangkok has attracted protesters, who want industrialized nations to allow low-cost generic versions of AIDS drugs to be available to the developing world. Protesters chanted slogans and focused on the plight of those with HIV, who need expensive drugs to stay alive. The U.N. Conference on Trade and Development, which meets only every four years, was founded to help foster cooperation between wealthy and developing nations. AIDS activists want to discuss the 1994 Trade Related Aspects of Intellectual Property agreement that gives drug companies sole worldwide patent rights to their drugs. These companies charge retail prices for AIDS drugs that are far above the budgets of people in developing countries; less than 2 percent of Thais with HIV can afford didanosine, and few Africans can at all. Thailand was threatened with sanctions on its products last year after it briefly considered producing cheap forms of didanosine.

Africa Conference's Huge Task: Turning Interest Into Action

"Africa Conference's Huge Task: Turning Interest Into Action" Washington Post (02/17/00) P. A2; Fletcher, Michael A.; Mufson, Steven
Rep. Alcee Hastings (D-Fla.) says that some African Americans in his district have shown very little concern about Africa's many problems because they have their own survival to carve out. "[Some people in] my district are as interested in day-to-day survival as the people in the Sudan are," he notes. Hastings, a member of the House International Relations subcommittee on Africa, is meeting with thousands of activists, business people, and others for a conference in Washington to try to change America's attitude towards Africa. Political leaders know they face an immense task, since few people in America strongly support specific African countries. The need for support for Africa is great, as AIDS ravages the continent, diseases orphan children by the thousands, and civil wars continue to rage.

Human Genome's Stock Soars

Washington Post (02/17/00) P. E3; Gillis, Justin
Human Genome Sciences has won patent rights for the CCR5 receptor protein, a key pathway that HIV uses to enter cells. Research has shown that people with defective CCR5 can remain immune to HIV for years. Currently, several pharmaceutical companies--including Human Genome--are investigating drugs that would block the gene in people with normal copies of it. News of the patent caused Human Genome's stock to soar on Wednesday, up 21 percent to $188.

Targeted Genetics to Collaborate on AIDS Vaccine

Reuters (02/16/00)
Seattle-based Targeted Genetics Corp. is joining the International AIDS Vaccine Initiative (IAVI) and the Children's Research Institute in Ohio to develop an AIDS vaccine. The vaccine will be made by using viral vector technology to put HIV genes into humans in order to generate a protective immune response. IAVI will invest over $6 million during the first three years of the collaboration. Targeted Genetics will receive exclusive rights to sell the vaccine, under certain conditions for selling it at a reasonable price.

Isles Better Already Good Role on Needle Exchange

"Isles Better Already Good Role on Needle Exchange" Honolulu Star-Bulletin Online (02/15/00); Altonn, Helen
Hawaii's syringe exchange program has improved in two areas, according to Don Des Jarlais, research director of the Chemical Dependency Institute at Beth Israel Medical Center in New York. The total number of syringes exchanged rose to an all-time high in 1999, and injection risk behavior dropped, with just 21 percent of those surveyed reporting that they shared needles in recent months. In his annual evaluation of the program, Des Jarlais found that syringe exchange clients in Hawaii are aging, with an average age of 42. He noted that 17 percent of AIDS cases in Hawaii stem from injection drug use and that heroin was the primary drug injected. While the expert praised Hawaii's syringe exchange program, he said the state must do more to address hepatitis B and C, "which, in Hawaii, are undoubtedly going to cause more illness and death than HIV." Des Jarlais recommended increasing hepatitis B vaccinations and putting more emphasis on the risks involved in sharing injection drug paraphernalia.

Grants Help Scientists Seek New Attack on AIDS

Reuters (02/16/00)
The American Foundation for AIDS Research (AmFAR) is using $875,000 in new grants to test compounds for preventing HIV infection. The money will be used to research microbicides, gels that can prevent sexually transmitted diseases like HIV and syphilis. The gels would give women a way to protect themselves other than condoms, which men may refuse to wear. Researchers from Montreal, Cornell University, and Belgium will examine using compounds in saliva, coconut oil, or shampoo to protect against HIV.

South Africa Faces Crack Scourge

Reuters (02/17/00); Swindells, Steven
Crack cocaine is rapidly taking hold in South Africa and could have serious consequences on the country's crime and AIDS rates. Quick action is needed to prevent a deadly crack scourge, which started among sex workers who then get their clients addicted. Heroin is also becoming more common, but crack is about to replace mandrax (methaqualone) as the No. 1 drug. Health workers note that crack and heroin could have devastating effects on South Africa's HIV rates; however, with prostitutes more willing to have unprotected sex in order to obtain more money to buy crack, the cycle is unlikely to end immediately.

AIDS-Hit Botswana Urged to Change Sex Behavior

Reuters (02/16/00); Baxter, Barry
President Festus Mogae of Botswana urged his citizens Wednesday to alter their sexual behavior to stop HIV's spread. AIDS threatens the economic success of the country, as the average life expectancy in Botswana has dropped to 45 years from 69 in the past decade. Speaking at a conference co-sponsored by the Harvard AIDS Institute, Mogae also noted that the stigma of AIDS often causes family members to shun each other and society.

stadtlander.com: HOME | HIV | BACK